PLK1 and cancer: The available data from other cancer cell lines indicated that MPNST cells have a uniquely high sensitivity toward gemcitabine and PLK1 inhibitors (Fig. 3B), which suggests that the biological processes inhibited by these drugs cannot be easily compensated by other pathways in MPNST cells, at least not within the timeframe of the compound screen.